芩珠凉血合剂治疗血热证银屑病的随机对照临床研究.doc

文档介绍：芩珠凉血合剂治疗血热证银屑病的随机对照临床研究
作者:李福伦, 李斌, 徐蓉, 宋勋, 余杨, 许铮城
【摘要】观察芩珠凉血合剂治疗血热证银屑病的临床疗效并探讨其部分作用机制。方法:58例辨证为血热证的寻常型银屑病患者,随机分为芩珠凉血合剂治疗组和西药复方氨肽素对照组,分别予以4周药物治疗。检测两组患者的血管内皮生长因子(vascular endothelial groatology Life Quality Index, DLQI)的差异,并采用银屑病面积严重程度指数(Psoriasis Area and Severity Index, PASI)评分法观察其临床疗效。结果:%,%,两组比较,差异有统计学意义(P<)。两组患者DLQI评分在用药2周及用药4周后均下降(P<);治疗组血清VEGF水平较治疗前降低(P<),而对照组用药前后VEGF水平差异无统计学意义(P>),两组治疗后VEGF水平比较,差异有统计学意义(P<)。
结论:芩珠凉血合剂能明显改善患者皮损状况和生活质量,其机制可能与下调患者血清VEGF水平,拮抗血管新生有关。
【关键词】血热; 银屑病; 临床研究
Objective: To explore the clinical efficacy of Qinzhu Liangxue Decoction (QZLXD), a pound traditional Chinese herbal medicine, in patients ly divided into tpeptide group (28 cases). Patients in both groups atology Life Quality Index (DLQI) score and the level of serum vascular endothelial : There peptide group (P<). The response rates in QZLXD and ampeptide groups proved during 4ent in QZLXD and ampeptide groups (P<). There peptide : QZLXD is remarkably advantageous in treatment of psoriasis vulgaris of bloodheat syndrome and improvement of patient's quality of life. The mechanism may be related to decrease in serum VEGF level and action against neogenesis of blood vessels.
Keyatology Life Quality Index, DLQI)评分。
治疗方法
治疗组予以芩珠凉血合剂口服(灵磁石30 g、珍珠母25 g、生牡蛎30 g、黄芩9 g、紫草